NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Xenetic Biosciences, Inc. (XBIO) Stock Analysis

Xenetic Biosciences, Inc. (XBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

XBIO

$2.02

+$0.02 (+1.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XBIO with… →

XBIO Key Statistics

As of Oct 21, 2026
Trading
Open
$2.00
Previous Close
$2.00
Day's Range
1.97–2.02
52-Week Range
1.85–4.94
Volume
6.84K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.20
Valuation
Market Cap
$4.73M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.45
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.15
Financials (FY)
Revenue (FY)
$2.98M+19.04%
Net Income (FY)
−$2.68M
Profit marginThe share of revenue left as profit after all costs and taxes.
−75.91%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.34M
1-Year Return
−47.80%
Dividend and dates
Avg Volume
87.63K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, XBIO closed at $2.02, −47.80% over 1 year.

Xenetic Biosciences, Inc. (XBIO) has a market capitalization of $4.73M.

In fiscal 2025, XBIO reported revenue of $2.98M.

XBIO Stock Return by Calendar Year

Xenetic Biosciences, Inc. (XBIO) 10-year return: what $10,000 became

1 year
$10,000 $5,220
−47.80%
5 years
$10,000 $1,122
−88.78%
10 years
$10,000 $38
−99.62%

If you had invested $10,000 in Xenetic Biosciences, Inc. (XBIO) 10 years ago, at the close on October 21, 2016, it would have been worth $38 at the close on October 21, 2026: −99.62% in total, −42.68% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.91%
2025−45.61%
2024+15.65%
2023+21.05%
2022−77.91%
2021−36.76%
2020+41.67%
2019−92.68%
2018−14.54%
2017−55.37%
2016 (partial year)−0.46%

As of October 21, 2026.

XBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.98M−$2.68M−90.1%
2024$2.50M−$3.96M−158.4%
2023$2.54M−$4.13M−162.8%
2022$1.71M−$6.55M−383.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.98M—−$2.83M−$2.68M−90.1%
2024$2.50M—−$4.20M−$3.96M−158.4%
2023$2.54M—−$4.52M−$4.13M−162.8%
2022$1.71M—−$6.72M−$6.55M−383.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XBIO Valuation vs Biotechnology Median

Median of 608 stocks
MetricXBIOBiotechnology medianvs median
P/S ratio1.4513.300.1x the median
Profit margin−75.91%−38.31%37.6 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Xenetic Biosciences, Inc. (XBIO) is capitalised at $4.73M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

Over the past 52 weeks the price has ranged from $1.85 to $4.94. XBIO last closed at $2.02 on October 21, 2026. That is +$0.02 (+1.00%) against the previous close. The latest close sits 9.19% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $2.98M. That is +19.04% against the prior fiscal year, when revenue was $2.50M. The same year closed with a net loss of $2.68M. Profit margin runs at −75.91%. That is 37.6 percentage points below the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −1.15.

Across the 4 fiscal years on file, revenue moves from $1.71M in 2022 to $2.98M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 1.45 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 2.2. Daily returns over the trailing 10 years annualize to a volatility of 134.68%. The trailing one-year total return is −47.80%. Across 10 years the annualized return works out at −42.68%.

Growth & Income

The record shows no dividend for XBIO.

So far in 2026 the total return is −6.91%. The strongest complete calendar year on file is 2020 at +41.67%; the weakest is 2019 at −92.68%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Xenetic Biosciences, Inc. (XBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Xenetic Biosciences, Inc. XBIO $4.73M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Xenetic Biosciences, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Visit website →